In this episode, listen to Matthew S. Davids, MD, MMSc​, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

• Contemporary treatment paradigms for patients with CLL
• Safety and efficacy of current regimens
• Molecular testing, including when and how to test for BTK inhibitor resistance
• Considering BTK inhibitor resistance when sequencing therapy

Program faculty:

Matthew S. Davids, MD, MMSc​
Associate Professor of Medicine​
Harvard Medical School​
Leader, Lymphoma Program​
Dana-Farber/Harvard Cancer Center​
Director of Clinical Research​
Division of Lymphoma​
Dana-Farber Cancer Institute​
Boston, Massachusetts​​

Lindsey Roeker, MD​
Assistant Attending​
CLL Program Director​
Department of Medicine​
Memorial Sloan Kettering Cancer Center​
New York, New York

Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

• Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
• Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
• Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
• The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC
  

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

• Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
• Long-term safety observations for crizotinib and entrectinib
• CNS activity of entrectinib and repotrectinib in patients with brain metastases
• Repotrectinib activity in ROS1-TKI resistance mutations
  

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

• ROS1-gene fusions in advanced lung cancer
• ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
• Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
• Advantages of RNA- vs DNA-based next-generation sequencing
  

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:

• RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancer
• RUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancer
• Survival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancer
• DUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancer
• Long-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatin
• Subgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancer
• Subgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancer
• Phase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapy
• innovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancer
• Randomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancer

Program faculty:

Floor J. Backes, MD
Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.

Presenters:
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Sarah Sammons, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/46hLGcM

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

• Prognostic variables when deciding between regimens
• Role of MRD in CLL
• Results from the phase II CAPTIVATE trial
• Choosing among the available covalent BTK inhibitors
• Preferred partner anti-CD20 antibody in CLL/SLL
• Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
• Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:

• Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
• Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
• Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
• Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
• Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
• JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
• Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
• Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib

Program faculty:

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Resources:
To download the slides associated with this podcast discussion, please visit the program page.